IDH305
CAS No. 1628805-46-8
IDH305( IDH-305 | IDH 305 )
Catalog No. M12434 CAS No. 1628805-46-8
IDH 305 (IDH305) is a potent, selective, brain penetrant mutant IDH1 inhibitor with IC50 of 18 and 28 nM for IDH1 R132H and R132C.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 115 | In Stock |
|
| 10MG | 160 | In Stock |
|
| 25MG | 332 | In Stock |
|
| 50MG | 502 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIDH305
-
NoteResearch use only, not for human use.
-
Brief DescriptionIDH 305 (IDH305) is a potent, selective, brain penetrant mutant IDH1 inhibitor with IC50 of 18 and 28 nM for IDH1 R132H and R132C.
-
DescriptionIDH 305 (IDH305) is a potent, selective, brain penetrant mutant IDH1 inhibitor with IC50 of 18 and 28 nM for IDH1 R132H and R132C; exhibits >200 fold selectivity over WT IDH1 (IC50=6.14 uM), and no activtiy against IDH2 mutants; inhibits EGF-independent proliferation of HCT116-IDH1R132H+/- cells with IC50 of 20 nM; exhibits in vivo correlation of 2-HG reduction and efficacy in IDH1 mutant xenograft tumor model.Brain Cancer Phase 1 Clinical.
-
In Vitro——
-
In VivoAnimal Model:nu/nu mice (HMEX2838-IDH1R132C+/-PDX model)Dosage:30, 100, 300 mg/kg Administration:Oral gavage; twice daily for 21 days Result:Resulted in 62-67% 2-HG reduction and significant anti-tumor activity at 100 mg/kg and 97-99% 2-HG reduction and partial tumor regression of 32% at 300 mg/kg.
-
SynonymsIDH-305 | IDH 305
-
PathwayMetabolic Enzyme/Protease
-
TargetIDH
-
RecptorIDH
-
Research AreaCancer
-
IndicationBrain Cancer
Chemical Information
-
CAS Number1628805-46-8
-
Formula Weight490.463
-
Molecular FormulaC23H22F4N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 150 mg/mL 305.84 mM
-
SMILESO=C1OC[C@H]([C@@H](F)C)N1C2=NC(N[C@H](C3=CC(C)=C(C4=CC(C(F)(F)F)=NC=C4)C=N3)C)=NC=C2
-
Chemical Name(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cho YS, et al. ACS Med Chem Lett. 2017 Sep 18;8(10):1116-1121.
molnova catalog
related products
-
BAY-1436032
BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively.
-
Enasidenib
An orally available, selective, potent inhibitor of mutant IDH2 with IC50s of 100-400 nM for IDH2R140Q homodimer.
-
Olutasidenib
Olutasidenib (FT-2102, FT2102) is an oral, highly potent, selective small molecule inhibitor of mutated IDH1 R132.
Cart
sales@molnova.com